
For the second time in less than a year, the U.S. Federal Trade Commission has released a highly critical report of pharmacy benefit managers, which play a crucial but opaque role in the pharmaceutical supply chain. And the findings may provide further impetus for legislative action to curb practices that critics say contribute to the rising cost of prescription drugs. The latest report accuses the PBMs — CVS Caremark, OptumRx, and Express Scripts, all of which are owned by large health insurers — of boosting prices of specialty generic drugs...